Friedman Michael, Gurpinar Berk, Lin Hsin-Ching, Schalch Paul, Joseph Ninos J
Department of Otolaryngology and Bronchoesophagology, Rush University Medical Center, Chicago, IL, USA.
Ann Otol Rhinol Laryngol. 2007 Nov;116(11):805-11. doi: 10.1177/000348940711601103.
We test the hypothesis that treatment of gastroesophageal reflux disease (GERD) can improve obstructive sleep apnea-hypopnea syndrome (OSAHS).
One hundred forty-six patients with OSAHS underwent a complete history-taking, physical examination, and laboratory testing, including questions related to GERD symptoms. Full-night attended polysomnography, 24-hour wireless pH study at the upper esophagus, snoring level evaluation, Epworth Sleepiness Scale, and quality-of-life surveys were completed for each patient. Patients who tested positive for GERD were treated with esomeprazole magnesium 40 mg once daily for 2 to 12 months. The 24-hour pH study was repeated, and those patients with elimination of GERD were reevaluated by polysomnography, snoring level evaluation, Epworth Sleepiness Scale, quality-of-life surveys, and subjective data collection.
Forty-one patients completed single-dose treatment with esomeprazole, but the repeat 24-hour pH study showed that 9 patients had persistent GERD. In the 29 patients who completed phase 2 with normal pH study findings, the snoring level decreased from 9.7 +/- 0.5 to 7.9 +/- 1.3 (p < .0001), the Epworth Sleepiness Scale score decreased from 14.2 +/- 2.5 to 11.1 +/- 2.4 (p < .0001), the apnea-hypopnea index decreased from 37.9 +/- 19.1 to 28.8 +/- 11.5 (p = .006), and the minimum saturation of oxygen increased from 84.1% +/- 7.8% to 86.9% +/- 5.0% (p = .055).
Treatment of GERD had a significant impact on the reduction of the apnea-hypopnea index, snoring, and daytime sleepiness. Elimination of GERD should be part of a comprehensive treatment plan for patients with OSAHS.
我们检验以下假设,即胃食管反流病(GERD)的治疗可改善阻塞性睡眠呼吸暂停低通气综合征(OSAHS)。
146例OSAHS患者接受了全面的病史采集、体格检查及实验室检查,包括与GERD症状相关的问题。为每位患者完成整夜多导睡眠监测、食管上段24小时无线pH值监测、打鼾程度评估、爱泼华嗜睡量表及生活质量调查。GERD检测呈阳性的患者接受埃索美拉唑镁40毫克每日一次治疗,疗程为2至12个月。重复进行24小时pH值监测,GERD消除的患者通过多导睡眠监测、打鼾程度评估、爱泼华嗜睡量表、生活质量调查及主观数据收集进行重新评估。
41例患者完成了埃索美拉唑单剂量治疗,但重复的24小时pH值监测显示,9例患者仍存在持续性GERD。在29例pH值监测结果正常且完成第二阶段治疗的患者中,打鼾程度从9.7±0.5降至7.9±1.3(p<0.0001),爱泼华嗜睡量表评分从14.2±2.5降至11.1±2.4(p<0.0001),呼吸暂停低通气指数从37.9±19.1降至28.8±11.5(p = 0.006),最低血氧饱和度从84.1%±7.8%升至86.9%±5.0%(p = 0.055)。
GERD的治疗对降低呼吸暂停低通气指数、打鼾及日间嗜睡有显著影响。消除GERD应成为OSAHS患者综合治疗方案的一部分。